Fiduciary Financial Group LLC Purchases 1,342 Shares of Amgen Inc. (NASDAQ:AMGN)

Fiduciary Financial Group LLC raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 121.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,445 shares of the medical research company's stock after acquiring an additional 1,342 shares during the quarter. Fiduciary Financial Group LLC's holdings in Amgen were worth $762,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also modified their holdings of the company. Ascent Wealth Partners LLC boosted its stake in shares of Amgen by 0.7% during the 4th quarter. Ascent Wealth Partners LLC now owns 9,024 shares of the medical research company's stock worth $2,352,000 after acquiring an additional 64 shares during the last quarter. ICICI Prudential Asset Management Co Ltd lifted its stake in shares of Amgen by 242.2% during the 4th quarter. ICICI Prudential Asset Management Co Ltd now owns 23,999 shares of the medical research company's stock valued at $6,255,000 after buying an additional 16,985 shares in the last quarter. Fisher Asset Management LLC lifted its stake in shares of Amgen by 285.4% during the 4th quarter. Fisher Asset Management LLC now owns 394,489 shares of the medical research company's stock valued at $102,820,000 after buying an additional 292,137 shares in the last quarter. Aire Advisors LLC lifted its stake in shares of Amgen by 26.3% during the 4th quarter. Aire Advisors LLC now owns 13,280 shares of the medical research company's stock valued at $3,461,000 after buying an additional 2,762 shares in the last quarter. Finally, Beacon Harbor Wealth Advisors Inc. purchased a new position in shares of Amgen during the 4th quarter valued at $3,531,000. Hedge funds and other institutional investors own 76.50% of the company's stock.

Wall Street Analysts Forecast Growth

AMGN has been the topic of a number of analyst reports. Cantor Fitzgerald initiated coverage on shares of Amgen in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $305.00 target price on the stock. Johnson Rice set a $294.00 target price on shares of Amgen in a research note on Wednesday, March 5th. UBS Group restated a "neutral" rating and set a $315.00 target price (down previously from $319.00) on shares of Amgen in a research note on Friday, May 2nd. Morgan Stanley restated an "equal weight" rating on shares of Amgen in a research note on Friday, May 2nd. Finally, Bank of America lifted their target price on shares of Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a research note on Wednesday, March 5th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $309.22.

Insider Activity at Amgen

In related news, SVP Rachna Khosla sold 1,500 shares of the company's stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $289.68, for a total transaction of $434,520.00. Following the transaction, the senior vice president now directly owns 8,162 shares in the company, valued at approximately $2,364,368.16. This represents a 15.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.76% of the stock is currently owned by insiders.

Amgen Price Performance

Shares of Amgen stock traded down $1.62 during trading hours on Wednesday, reaching $291.81. The company's stock had a trading volume of 1,827,452 shares, compared to its average volume of 2,812,318. The firm has a 50 day moving average price of $280.93 and a 200-day moving average price of $285.41. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The stock has a market cap of $156.91 billion, a P/E ratio of 38.65, a P/E/G ratio of 2.63 and a beta of 0.51.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, topping analysts' consensus estimates of $4.18 by $0.72. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The firm had revenue of $8.15 billion for the quarter, compared to the consensus estimate of $8.05 billion. During the same period in the previous year, the firm posted $3.96 EPS. The business's quarterly revenue was up 9.4% on a year-over-year basis. On average, analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.